Kst-6051

KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)

Kestrel Therapeutics, Inc.Phase 1

—

Rating in progress

Kst-6051 in KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.

Methodology v0.2 · Active